PL3681512T3 - Abx196 do zastosowania w leczeniu raka pęcherza moczowego - Google Patents

Abx196 do zastosowania w leczeniu raka pęcherza moczowego

Info

Publication number
PL3681512T3
PL3681512T3 PL18765477T PL18765477T PL3681512T3 PL 3681512 T3 PL3681512 T3 PL 3681512T3 PL 18765477 T PL18765477 T PL 18765477T PL 18765477 T PL18765477 T PL 18765477T PL 3681512 T3 PL3681512 T3 PL 3681512T3
Authority
PL
Poland
Prior art keywords
abx196
treatment
bladder cancer
bladder
cancer
Prior art date
Application number
PL18765477T
Other languages
English (en)
Inventor
Sandrine CRABE
Didier Scherrer
Hartmut Ehrlich
Philippe Pouletty
Original Assignee
Abivax
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abivax filed Critical Abivax
Publication of PL3681512T3 publication Critical patent/PL3681512T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL18765477T 2017-09-13 2018-09-13 Abx196 do zastosowania w leczeniu raka pęcherza moczowego PL3681512T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17306182 2017-09-13
PCT/EP2018/074778 WO2019053142A1 (en) 2017-09-13 2018-09-13 ABX196 FOR USE IN THE TREATMENT OF BLADDER CANCER
EP18765477.7A EP3681512B1 (en) 2017-09-13 2018-09-13 Abx196 for use in the treatment of bladder cancer

Publications (1)

Publication Number Publication Date
PL3681512T3 true PL3681512T3 (pl) 2022-01-17

Family

ID=60001797

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18765477T PL3681512T3 (pl) 2017-09-13 2018-09-13 Abx196 do zastosowania w leczeniu raka pęcherza moczowego

Country Status (18)

Country Link
US (1) US11266667B2 (pl)
EP (1) EP3681512B1 (pl)
JP (1) JP7214718B2 (pl)
KR (1) KR102706165B1 (pl)
CN (1) CN111182907B (pl)
AU (1) AU2018332046B2 (pl)
BR (1) BR112020004778A2 (pl)
CA (1) CA3075443A1 (pl)
CU (1) CU20200020A7 (pl)
DK (1) DK3681512T3 (pl)
ES (1) ES2893549T3 (pl)
HR (1) HRP20211351T1 (pl)
IL (1) IL273054B2 (pl)
MX (1) MX394216B (pl)
PL (1) PL3681512T3 (pl)
PT (1) PT3681512T (pl)
WO (1) WO2019053142A1 (pl)
ZA (1) ZA202001435B (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117222414A (zh) 2021-03-01 2023-12-12 脱落性治疗公司 用于激活恒定自然杀伤t-细胞的化合物和用于消除炎性衰老细胞的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207135B2 (en) * 2007-12-05 2012-06-26 Wittycell Compositions for and methods of enhancing the immune response to antigens
JP5809560B2 (ja) * 2008-10-08 2015-11-11 アビヴァックス インフルエンザに対して使用するためのワクチン組成物
HK1197068A1 (en) * 2011-01-05 2015-01-02 台湾大学 Methods for preparation of glycosphingolipids and uses thereof
BR112019004906A2 (pt) 2016-09-14 2019-06-25 Abivax combinação incluindo abx196 para o tratamento de câncer

Also Published As

Publication number Publication date
US20200230163A1 (en) 2020-07-23
RU2020109889A3 (pl) 2022-01-28
AU2018332046A1 (en) 2020-03-19
HRP20211351T1 (hr) 2021-11-26
JP2020533368A (ja) 2020-11-19
EP3681512B1 (en) 2021-08-04
CN111182907A (zh) 2020-05-19
ES2893549T3 (es) 2022-02-09
CA3075443A1 (en) 2019-03-21
CN111182907B (zh) 2023-01-06
WO2019053142A1 (en) 2019-03-21
US11266667B2 (en) 2022-03-08
EP3681512A1 (en) 2020-07-22
AU2018332046B2 (en) 2024-06-13
ZA202001435B (en) 2022-07-27
MX2020002812A (es) 2020-07-21
IL273054B1 (en) 2023-01-01
BR112020004778A2 (pt) 2020-10-13
JP7214718B2 (ja) 2023-01-30
KR20200102412A (ko) 2020-08-31
CU20200020A7 (es) 2020-11-30
DK3681512T3 (da) 2021-09-06
KR102706165B1 (ko) 2024-09-13
RU2020109889A (ru) 2021-09-06
PT3681512T (pt) 2021-10-06
MX394216B (es) 2025-03-24
IL273054A (en) 2020-04-30
IL273054B2 (en) 2023-05-01

Similar Documents

Publication Publication Date Title
HRP20180876T1 (hr) Adc duokarmicina, namijenjeni upotrebi u liječenju raka mokraćnog mjehura
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
IL248455B (en) igf-1r antibody-drug conjugate and its use for cancer treatment
ZA201803742B (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
IL276733A (en) Use of Aribolin in cancer treatment
LT3806898T (lt) Gremlin-1 antagonistas, skirtas naudoti vėžio gydymui
IL248767B (en) Trimethoxyphenyl-benzaimidazole compounds for cancer treatment
PL3253208T3 (pl) Terapie kombinowane do zastosowania w leczeniu nowotworu piersi
IL273863A (en) Hemorrhoid treatment device
SG10202001388YA (en) Use of ureidomustine (bo-1055) in cancer treatment
PL3258931T3 (pl) Zastosowanie kabazitakselu w leczeniu nowotworu złośliwego prostaty
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
IL269121A (en) Usl-311 for use in the treatment of cancer
SG11202011434SA (en) Methods for the treatment of bladder cancer
ZA202001435B (en) Abx196 for use in the treatment of bladder cancer
GB2578008B (en) 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment
HK40018432A (en) Usl-311 for use in the treatment of cancer
IL268265B (en) 3-beta-hydroxy-5-alpha-paragnane-20-one for use in medical treatment